Enrolling by invitationPhase 3NCT06908226
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
Studying Infantile epileptic-dyskinetic encephalopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Longboard Pharmaceuticals
- Intervention
- LP352(drug)
- Enrollment
- 324 enrolled
- Eligibility
- 2-66 years · All sexes
- Timeline
- 2025 – 2027
Study locations (16)
- Arkansas Children's Hospital - PIN, Little Rock, Arkansas, United States
- David Geffen School of Medicine at UCLA, Los Angeles, California, United States
- NW FL Clinical Research Group, LLC, Gulf Breeze, Florida, United States
- Research Institute of Orlando LLC, Orlando, Florida, United States
- Pediatric Epilepsy and Neurology Specialists, Tampa, Florida, United States
- Mid-Atlantic Epilepsy and Sleep Center, Bethesda, Maryland, United States
- Institute of Neurology and Neurosurgery at Saint Barnabas, LLC, Livingston, New Jersey, United States
- Northeast Regional Epilepsy Group - Morristown - 310 Madison Ave, Morristown, New Jersey, United States
- The University of Texas Medical School at Houston, Houston, Texas, United States
- Austin Hospital, Heidelberg, Victoria, Australia
- AP-HP - Hôpital universitaire Robert-Debré, Paris, France
- Children's Clinical University Hospital, Riga, Latvia
- Mother and Child Health Care Institute of Serbia Dr Vukan Cupic, Belgrade, Serbia
- Hospital de La Santa Creu i Sant Pau, Barcelona, Spain
- Hospital Universitario Vithas Madrid La Milagrosa, Madrid, Spain
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06908226 on ClinicalTrials.gov